Skip to main content

Healthy Participants Study

6
Pipeline Programs
7
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 7 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Candid Therapeutics
Candid TherapeuticsCA - San Diego
2 programs
2
CND319Phase 11 trial
cizutamigPhase 11 trial
Active Trials
NCT07712939Recruiting105Est. Mar 2028
NCT07236411Completed24Est. Jul 2026
Alzheon
AlzheonMA - Framingham
1 program
1
ALZ-507Phase 11 trial
Active Trials
NCT07824271Recruiting84Est. Nov 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD0292Phase 11 trial
Active Trials
NCT06311760Completed32Est. Feb 2025
Kymera Therapeutics
Kymera TherapeuticsMA - Watertown
1 program
1
KT-621Phase 11 trial
Active Trials
NCT06673667Completed118Est. Apr 2025
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLS2312 InjectionPhase 11 trial
Active Trials
NCT07861581Not Yet Recruiting70Est. Nov 2027
Parexel
ParexelMA - Boston
1 program
AnifrolumabPHASE_1Monoclonal Antibody
Prothena
ProthenaDUBLIN 2, Ireland
1 program
PRX019PHASE_11 trial
Active Trials
NCT06699680Completed50Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Qilu PharmaceuticalQLS2312 Injection
Candid TherapeuticsCND319
AlzheonALZ-507
Candid Therapeuticscizutamig
ProthenaPRX019
Kymera TherapeuticsKT-621
AstraZenecaAZD0292

Clinical Trials (7)

Total enrollment: 483 patients across 7 trials

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection

Start: Nov 2026Est. completion: Nov 202770 patients
Phase 1Not Yet Recruiting

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

Start: Jul 2026Est. completion: Mar 2028105 patients
Phase 1Recruiting

Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults

Start: Mar 2026Est. completion: Nov 202684 patients
Phase 1Recruiting

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

Start: Dec 2025Est. completion: Jul 202624 patients
Phase 1Completed

Phase 1 Study of PRX019 in Healthy Adult Volunteers

Start: Nov 2024Est. completion: Jan 202650 patients
Phase 1Completed

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

Start: Oct 2024Est. completion: Apr 2025118 patients
Phase 1Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Start: Apr 2024Est. completion: Feb 202532 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 483 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Healthy Participants Study | Pipeline & Competitive Landscape | Formulate